| Primary |
| Antifungal Prophylaxis |
33.3% |
| Prophylaxis |
22.7% |
| Pneumocystis Jiroveci Pneumonia |
6.7% |
| Arthropod Bite |
5.3% |
| Dermatitis Herpetiformis |
4.0% |
| Infection |
4.0% |
| Antibiotic Prophylaxis |
2.7% |
| Dermatitis |
2.7% |
| Erythema Marginatum |
2.7% |
| Hiv Infection |
2.7% |
| Acne |
1.3% |
| Blister |
1.3% |
| Cd4 Lymphocytes Decreased |
1.3% |
| Cellulitis |
1.3% |
| Deep Vein Thrombosis |
1.3% |
| Drug Hypersensitivity |
1.3% |
| Fungal Infection |
1.3% |
| Hidradenitis |
1.3% |
| Hyperuricemia |
1.3% |
| Immune System Disorder |
1.3% |
|
| Methaemoglobinaemia |
30.8% |
| Oxygen Saturation Decreased |
10.8% |
| Haemolytic Anaemia |
9.2% |
| Toxic Epidermal Necrolysis |
9.2% |
| Rash |
4.6% |
| Swelling Face |
4.6% |
| Anaemia |
3.1% |
| Cough |
3.1% |
| Pneumonia |
3.1% |
| Pyrexia |
3.1% |
| Renal Failure Acute |
3.1% |
| Respiratory Distress |
3.1% |
| Acute Respiratory Failure |
1.5% |
| Aphagia |
1.5% |
| Blood Methaemoglobin |
1.5% |
| Cyanosis |
1.5% |
| Dyspnoea |
1.5% |
| Febrile Neutropenia |
1.5% |
| Haemolysis |
1.5% |
| Hypoxia |
1.5% |
|
| Secondary |
| Product Used For Unknown Indication |
15.1% |
| Behcet's Syndrome |
12.8% |
| Prophylaxis |
12.8% |
| Hiv Infection |
10.9% |
| Conjunctivitis |
8.0% |
| Immunosuppression |
5.9% |
| Leprosy |
4.9% |
| Pemphigus |
4.6% |
| Drug Exposure During Pregnancy |
4.2% |
| Drug Use For Unknown Indication |
3.7% |
| Mycobacterium Avium Complex Infection |
2.8% |
| Antifungal Prophylaxis |
2.1% |
| Pemphigoid |
1.8% |
| Pyoderma Gangrenosum |
1.8% |
| Lepromatous Leprosy |
1.6% |
| Depression |
1.6% |
| Leukocytoclastic Vasculitis |
1.5% |
| Pneumocystis Jiroveci Pneumonia |
1.4% |
| Toxoplasmosis |
1.4% |
| Antiretroviral Therapy |
1.3% |
|
| Methaemoglobinaemia |
9.6% |
| White Blood Cell Count Increased |
8.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
7.2% |
| Renal Tubular Necrosis |
6.4% |
| Sepsis |
6.4% |
| Rash |
5.6% |
| Drug Hypersensitivity |
4.8% |
| Polyglandular Disorder |
4.8% |
| Pregnancy |
4.8% |
| Squamous Cell Carcinoma |
4.8% |
| Squamous Cell Carcinoma Of Skin |
4.8% |
| Drug Ineffective |
4.0% |
| Haemolytic Anaemia |
4.0% |
| Rash Pustular |
4.0% |
| Staphylococcal Infection |
4.0% |
| Tachycardia |
4.0% |
| Drug Exposure During Pregnancy |
3.2% |
| Hydrocephalus |
3.2% |
| Kaposi's Sarcoma |
3.2% |
| Rebound Effect |
3.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.2% |
| Hiv Infection |
21.5% |
| Drug Use For Unknown Indication |
18.9% |
| Prophylaxis |
3.8% |
| Antifungal Prophylaxis |
3.5% |
| Acne |
3.5% |
| Hypertension |
2.9% |
| Multiple Myeloma |
2.8% |
| Pain |
2.3% |
| Diabetes Mellitus |
2.1% |
| Chronic Lymphocytic Leukaemia |
1.6% |
| Depression |
1.6% |
| Acute Lymphocytic Leukaemia |
1.6% |
| Diffuse Large B-cell Lymphoma |
1.6% |
| Infection Prophylaxis |
1.6% |
| Prophylaxis Against Transplant Rejection |
1.5% |
| Idiopathic Thrombocytopenic Purpura |
1.4% |
| Acute Myeloid Leukaemia |
1.3% |
| Nausea |
1.2% |
| Gastrooesophageal Reflux Disease |
1.2% |
|
| Vomiting |
8.1% |
| White Blood Cell Count Decreased |
7.7% |
| Renal Failure Acute |
7.2% |
| Pneumonia |
6.8% |
| Thrombocytopenia |
6.2% |
| Sepsis |
6.0% |
| Pyrexia |
5.8% |
| Myocardial Infarction |
5.4% |
| Weight Decreased |
5.2% |
| Weight Increased |
5.0% |
| Renal Failure |
4.8% |
| Rash |
4.6% |
| Venous Thrombosis Limb |
4.6% |
| Death |
3.7% |
| Pain |
3.7% |
| Vitamin B12 Deficiency |
3.7% |
| Respiratory Failure |
3.1% |
| Syncope |
3.1% |
| Drug Ineffective |
2.7% |
| Dyspnoea |
2.7% |
|
| Interacting |
| Product Used For Unknown Indication |
18.8% |
| Graft Versus Host Disease |
10.1% |
| Antiretroviral Therapy |
8.7% |
| Hiv Infection |
8.7% |
| Prophylaxis |
8.7% |
| Hypertension |
5.8% |
| Localised Infection |
5.8% |
| Anaemia |
4.3% |
| Hormone Replacement Therapy |
4.3% |
| Thrombophlebitis |
4.3% |
| Deep Vein Thrombosis |
2.9% |
| Herpes Zoster |
2.9% |
| Pain |
2.9% |
| Pulmonary Embolism |
2.9% |
| Blast Crisis In Myelogenous Leukaemia |
1.4% |
| Bronchial Disorder |
1.4% |
| Depression |
1.4% |
| Diabetes Mellitus |
1.4% |
| Diuretic Therapy |
1.4% |
| Dyspepsia |
1.4% |
|
| Toxic Epidermal Necrolysis |
33.3% |
| Haemolytic Anaemia |
22.2% |
| Drug Interaction |
11.1% |
| International Normalised Ratio Increased |
11.1% |
| Pericardial Effusion |
11.1% |
| White Blood Cell Count Increased |
11.1% |
|
